Safety, tolerability and pharmacokinetics of TAS-108, a novel anti-oestrogen, in healthy post-menopausal Japanese women: A phase i single oral dose study

Basic and Clinical Pharmacology and Toxicology

Volumn 104, Issue 5, 2009, Pages 352-359

  Kumagai, Yuji ^a   Fujita, Tomoe ^a   Ozaki, MacHiko ^a   Yokota, Shin Ichi ^a   Maeda, Mika ^a   Shida, Mizue ^a   Otani, Yoshio ^a   Yamaya, Hidetoshi ^b   Tsuruta, Hideo ^b  

^a KITASATO UNIVERSITY   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

21 (4 DIETHYLAMINOMETHYL 2 METHOXYPHENOXY) 7ALPHA METHYL 19 NORPREGNA 1,3,5(10) TRIEN 3 OL; DRUG METABOLITE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; FLUSHING; FOOD; FOOD DRUG INTERACTION; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; HYPERHIDROSIS; JAPANESE; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; NORMAL HUMAN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; POSITIONAL DIZZINESS; POSTMENOPAUSE; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; HUMANS; JAPAN; MIDDLE AGED; POSTMENOPAUSE;

EID: 64549133867     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00373.x     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008 58 : 71 96.
2. Kawamura T, Sobue T. Comparison of breast cancer mortality in five countries: France, Italy, Japan, the UK and the USA from the WHO mortality database (1960-2000). Jpn J Clin Oncol 2005 35 : 758 9.
3. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005 365 : 1687 717.
4. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992 339 : 1 15.
5. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998 351 : 1451 67.
6. Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W et al. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin 2006 22 : 1575 85.
7. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003 98 : 1802 10.
8. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005 353 : 2747 57.
9. Nabholtz JM, Bonneterre J, Buzdar A, Robertson JF, Thürlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003 39 : 1684 9.
10. Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003 21 : 2101 9.
11. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 2000 356 : 881 7.
12. Lipton A, Harvey HA, Hamilton RW. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 1984 68 : 887 9.
13. Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 1998 83 : 1158 62.
14. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990 82 : 1327 32.
15. Howell A, Dodwell DJ, Anderson H, Redford J. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 1992 3 : 611 7.
16. Yamamoto Y, Wada O, Takada I, Yogiashi Y, Shibata J, Yanagisawa J et al. Both N- and C-terminal transactivation functions of DNA-bound ERα are blocked by a novel synthetic estrogen ligand. Biochem Biophys Res Commun 2003 312 : 656 62.
17. Yamamoto Y, Shibata J, Yonekura K, Sato K, Hashimoto A, Aoyagi Y et al. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor α and a partial agonist on estrogen receptor b with low uterotrophic effect. Clin Cancer Res 2005 11 : 315 22.
18. 14C]TAS-108) and its metabolites after single oral administration to rats bearing 7,12-dimethylbenz(α)anthracene-induced mammary tumor. Drug Metab Dispos 2006 34 : 331 8.
19. Blakely LJ, Buzdar A, Chang HY, Frye D, Theriault R, Valero V et al. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer. Clin Cancer Res 2004 10 : 5425 31.
20. Yamaya H, Yoshida K, Kuritani J, Yonezawa J, Tsuda M, Shindo T et al. Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose. J Clin Pharm Ther 2005 30 : 459 70.
21. Gibaldi M, Perrier D (eds). Pharmacokinetics, 2nd edn (revised and expanded). Marcel Dekker, Inc., New York, 1982.
22. Sokal RR, Rohlf FJ (eds). Biometry: the Principles and Practice of Statistics in Biological Research, 3rd edn. WH Freeman & Company, San Francisco, CA, 1995 440 4.